Many regain weight after stopping GLP-1 drugs, data shows. Here’s why
People on average regain weight at a rate of 0.4 kg/month after they stopped taking their weight loss medications, a review of 63 trials covering over 9,000 individuals showed.
Kallyope eyes clinic with K-554 for obesity
Kallyope Inc. has outlined plans to initiate phase I studies this year with K-554, a non-incretin peptide candidate offering a new mechanism of action in obesity.
7 CES 2026 technologies that made science fiction feel uncomfortably practical
CES 2026 had no shortage of AI products, but a quieter pattern stood out across booths that had little else in common. Some of the most attention-grabbing technologies weren’t built for screens or productivity dashboards. They were built to be eerily close to us, and for personal spaces like bathrooms, bedrooms, desks, and even the […]
STAT+: Eli Lilly’s Zepbound, on top of immunology drug, helped reduce psoriatic arthritis symptoms
Eli Lilly said Thursday that adding its weight loss drug Zepbound on top of its immunology therapy Taltz helped obese patients with an autoimmune condition that causes joint pain more than Taltz did alone. The data suggest the GLP-1 drug Zepbound, which has already been shown to help with obesity and sleep apnea, among other […]
New Lilly data suggest Zepbound boosted effect of autoimmune drug
New Phase 3b data from Eli Lilly suggest that its blockbuster weight loss drug helped boost the efficacy of an autoimmune treatment in select patients with active psoriatic arthritis who were overweight or obese. …
Is LLY’s Ventyx Deal Another Attempt at Diversification Beyond GLP-1?
Eli Lilly LLY has pursued a series of acquisitions since early 2025 to strengthen its pipeline and support long-term growth amid intensifying competition in the obesity space. While cardiometabolic health remains its core focus, LLY is deliberately broadening its footprint into other therapeutic areas, such as oncology, neuroscience, ophthalmology, and immunology, through targeted deals. Eli Lilly […]
Former GLP-1 users regain lost weight after about 18 months, study says – The Washington Post
Former GLP-1 users regain lost weight after about 18 months, study says The Washington Post People Who Stop Taking Weight-Loss Medications Regain Weight Within 2 Years, Study Says People.com Less than two years after stopping obesity drugs, weight and health issues return, study finds Reuters Obesity drug users will regain weight two years after ending medication, review finds Financial […]
The 20 most influential drug approvals of 2025: GoodRx
GoodRx has named 20 medications and vaccines as the most influential FDA approvals of 2025, spotlighting first-in-class drugs, new indications, and therapies with the potential to significantly affect public health. 1. Nereus (tradipitant) for motion sickness: Approved Dec. 30, Nereus is the first new prescription drug in decades for motion sickness. The oral capsule works […]
GLP-1 receptor agonists tied to reduced acute asthma exacerbations in teens with overweight, obesity
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a lower risk for acute asthma exacerbations in adolescents with overweight or obesity, according to a research letter published online Dec. 29 in JAMA Network Open.
GLP-1 Market Trends and Global Forecasts 2025-2035: 150+ Candidates Intended for the Treatment of Multiple Indications, are Currently Either Approved or Being Investigated – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “GLP-1 Market: Industry Trends and Global Forecasts, Till 2035” report has been added to ResearchAndMarkets.com’s offering. The global GLP-1 market is estimated to grow from USD 62.2 billion in the current year to USD 157.5 billion by 2035, at a CAGR of 9.7% during the forecast period, till 2035. The efficacy of GLP-1 […]